The invention relates to compounds of formula (I) wherein R
1
, R
2
, X
1
, X
2
, Y, R
a
, R
b
, Q have the meanings given in claim
1
. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.
The present invention relates to methods for changing the load state of MHC molecules with ligands, the change in the load state being catalysed by a compound of formulae I, IA, II, III or IV1 to IV3. The invention relates further to the use of compounds of formulae I, IA, II, III or IV1 to IV3 or to the use of MHC molecules loaded with ligands, which molecules can be prepared by a method according to the invention, for the treatment of disorders or conditions that are associated with various pathologically excessive or absent immune responses and also for triggering tumour-specific, pathogen-specific or autoreactive immune responses. The invention additionally relates to the use of such compounds for the treatment and diagnosis of cancer, infectious diseases, autoimmune diseases and for attenuating aggressive immune reactions, as well as to the preparation of a vaccine or of a pharmaceutical composition for the treatment of the mentioned disorders or conditions.
US9006454B2
申请人:——
公开号:US9006454B2
公开(公告)日:2015-04-14
[EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE LA DIHYDROOROTATE DÉSHYDROGÉNASE
申请人:MERCK SERONO SA
公开号:WO2010115736A2
公开(公告)日:2010-10-14
The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.